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ABSTRACT
Although vaccines and antiretroviral (ARV) prevention have demonstrated partial success against human immunodeficiency
virus (HIV) infection in clinical trials, their combined introduction could provide more potent protection. Furthermore, combi-
nation approaches could ameliorate the potential increased risk of infection following vaccination in the absence of protective
immunity. We used a nonhuman primate model to determine potential interactions of combining a partially effective ARVmi-
crobicide with an envelope-based vaccine. The vaccine alone provided no protection from infection following 12 consecutive
low-dose intravaginal challenges with simian-HIV strain SF162P3, with more animals infected compared to naive controls. The
microbicide alone provided a 68% reduction in the risk of infection relative to that of the vaccine group and a 45% reduction
relative to that of naive controls. The vaccine-microbicide combination provided an 88% reduction in the per-exposure risk of
infection relative to the vaccine alone and a 79% reduction relative to that of the controls. Protected animals in the vaccine-micro-
bicide groupwere challenged a further 12 times in the absence ofmicrobicide anddemonstrated a 98% reduction in the risk of infec-
tion. A total risk reduction of 91%was observed in this group over 24 exposures (P 0.004). These important findings suggest that
combined implementation of newbiomedical prevention strategiesmay provide significant gains inHIVprevention.
IMPORTANCE
There is a pressing need to maximize the impact of new biomedical prevention tools in the face of the 2 million HIV infections
that occur each year. Combined implementation of complementary biomedical approaches could create additive or synergistic
effects that drive improved reduction of HIV incidence. Therefore, we assessed a combination of an untested vaccine with an
ARV-based microbicide in a nonhuman primate vaginal challenge model. The vaccine alone provided no protection (andmay
have increased susceptibility to a simian-HIV vaginal challenge), while the microbicide reduced the infection risk compared to
that of vaccinated and naive animals. Importantly, the combined interventions provided the greatest level of protection, which
was sustained following withdrawal of the microbicide. The data suggest that provision of ARV prophylaxis during vaccination
reduces the potential for unexpected increased risks of infection following immunization and augments vaccine efficacy. These
findings are important for the potential adoption of ARV prophylaxis as the baseline intervention for future HIV/AIDS vaccines.
The Thai RV144 vaccine trial, based on a canarypox virus vectorprime-protein boost, is the first clinical trial to have shown
moderate efficacy (31.2%) in cohorts at low risk of human immu-
nodeficiency virus (HIV) exposure (1). Partial protection has also
been achieved by other new biomedical approaches, including the
use of antiretroviral (ARV) drugs for oral (44 to 75%) or topical
(vaginal, 39%) preexposure prophylaxis (PrEP) (2–5). However,
effectiveness was dependent upon consistent product use and im-
pacted bymultiple factors influencing susceptibility and exposure
risk (6). Three decades of research on combined implementa-
tion of structural and behavioral interventions have indicated
that combination approaches are more effective than any single
intervention alone (7). Additional potential gains could be re-
alized by assessing the impact of combining new biomedical
prevention strategies (8). Indeed, a positive impact would be
seen if combining ARV prevention and vaccines provided better
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protection than either intervention alone. Here, a reduction of the
number of transmitted strains and/or a delay in the initial viral
expansion phasemight buy time formore effective immune clear-
ance. Conversely, systemic immunitymight curtail the dissemina-
tion of virus that bypasses the activity of topically applied ARVs.
Furthermore, protection from productive infection on repeat
exposure to HIV when using ARV prevention might evoke expo-
sure-induced immunity. This could serve to modify vaccine-in-
duced immune responses to better recognize a prevalent circulat-
ing virus. Indeed, evidence from some nonhuman primate (NHP)
studies indicates that animals exposed to infectious virus when
protected by PrEP demonstrate cellular immune responses to the
challenge virus (9, 10). However, such immune responses in
these nonvaccinated animals appeared insufficient to protect
animals from a subsequent challenge in the absence of PrEP
(10). Conversely, combinations could also have potential neg-
ative interactions. Certain vaccine-induced immune activation
may have the potential to increase mucosal HIV-1 susceptibil-
ity (11, 12) that, in combination, could reduce the efficacy of
ARV prevention. This has important implications, given that
increased sensitivity over the potential of novel vaccines to
enhance the risk of HIV acquisition may drive the adoption of
oral PrEP provision as the baseline intervention for future
HIV/AIDS vaccine trials.
MATERIALS AND METHODS
Ethics statement. All 50 Mauritius-origin, outbred, young adult (4 to 6
years old), female cynomolgus monkeys (Macaca fascicularis) used were
housed in the Commissariat a l’Energie Atomique (CEA) facilities (Fon-
tenay-aux-Roses, France; CEA accreditation no. B 92-032-02) in compli-
ance with the National Institutes of Health (NIH) Office of Laboratory
Animal Welfare Guide for the Humane Care and Use of Laboratory Ani-
mals. This study and the procedures used were approved by the Comité
Régional d’Ethique pour l’Expérimentation Animale Ile-de-France Sud
(notification no. 10-062). All experimental procedures were carried out
FIG 1 Vaccination-and-challenge schedules with longitudinal serum antibody responses in the VM group prechallenge. (A) Schematic representation of
vaccination-and-challenge schedules. Groups: V, vaccine alone; VM, vaccine plusmicrobicide;M,microbicide alone; C, control. Green vertical arrows indicate
i.n. vaccinations with R848 at weeks 0, 4 and 8; red vertical arrows indicate i.m. vaccinations with MF59 at weeks (w) 16 and 28; blue vertical arrows indicate 12
challenges in the absence of microbicide (weeks 39 to 59 and 60 to 80); and black vertical arrows indicate 12 challenges in the presence of microbicide (weeks 39
to 60). (B to E) SF162 serum IgG responses (B), SF162 serum IgA responses (C), TV-1 serum IgG responses (D), and serum IgA TV-1 responses (E) in the VM
group, all prechallenge.
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in the CEA animal facility in strict compliance with European guide-
lines for NHP care (European Directive 86/609 then; as of January
2013, EU Directive N 2010/63/EU) for protection of animals used for
experimentation and other scientific purposes and the Weatherall re-
port. Monitoring of the animals was under the supervision of the
veterinarians in charge of the animal facilities. All efforts were made to
minimize suffering, including improved housing conditions with en-
richment opportunities (e.g., 12-h light–12-h dark scheduling, provi-
sion of treats such as biscuits supplemented with fresh fruit, and con-
stant access to a water supply, in addition to regular play interaction
with staff caregivers and research staff). Experimental procedures were
performed while animals were under anesthesia with ketamine at 10
mg/kg (body weight). Euthanasia was performed prior to the develop-
ment of symptoms of disease (indicated by a rapid decline in CD4 T
cells and/or an increase in viremia) and was performed by the intrave-
nous injection of a lethal dose of pentobarbital. All 50 animals de-
scribed were experimentally naive at the beginning of the study. Inves-
tigators were blind to the group allocations while performing
immunological and virological assessments.
Cynomolgus macaque combinedmicrobicide-vaccine study. Teno-
fovir gel (1%) or a control placebo gel, a proprietary formulation contain-
ing purified water with EDTA, citric acid, glycerin, methylparaben, pro-
pylparaben, and hydroxyethylcellulose (pH 4.5) provided by CONRAD
(Arlington, VA), was transferred to 5-ml syringes and administered in
2-ml volumes via a 10FG soft catheter introduced2 cm into the vagina.
The process was atraumatic with no obvious leakage and was carried out
while the animals were under anesthesia. Vaccine antigens, uncleaved
gp140 TV1 and SF162, and MF59 adjuvant were provided and manu-
factured by Novartis. For each intranasal (i.n.) immunization, 50 g
each of TV-1 and SF162 gp140 was given in solution in a volume of 0.2
ml containing 500 g of Resiquamod (R848) a TLR7/8 agonist (Invi-
voGen). The solution was dropped into each of the anterior nares of
sedated animals placed in a prone position with their heads tilted back.
For intramuscular (i.m.) immunizations, 100 g each of TV-1 and
SF162 gp140 was mixed with MF59 adjuvant and given in a volume of
0.4 ml into the deltoid muscle of the upper arm. Vaccinated cynomol-
gus macaques received three i.n. priming immunizations (0, 4, and 8
weeks), followed by two i.m. boost immunizations (16 and 28 weeks).
Challenge studies were commenced 11 weeks after the final boost im-
munization.
Fifty Mauritius-origin, outbred, young adult (4 to 6 years old), female
cynomolgus monkeys (M. fascicularis) were used for this study. No ran-
domization was used; however, groups were balanced for susceptible
and resistant major histocompatibility complex (MHC) haplotypes
(H2, H6, and H4) (13). Recent studies demonstrated that the TRIM5
genotype has no impact on virus acquisition or vaccination outcome
(14). Sample size was chosen knowing that 90% infection was expected
in the control group on the basis of previous titration of the challenge
stock. A sample size of 16 for each of the microbicide (M) and vaccine-
plus-microbicide (VM) groups was chosen with an 80% power to
detect an increase in the survival proportion of 0.53 with a significance
level () of 0.05 (two-tailed log rank test). A sample size of 12 animals
for the controls provided an 80% power to detect an efficacy of 67% in
the other groups.
Only eight animals were available for inclusion in the vaccine (V)
group; however, this number was estimated to be sufficient to prove that
the vaccine alone was ineffective at preventing infection. Investigators
performing the animal studies were not blind to the group allocation. On
the day of a challenge, 2 ml of the microbicide gel was applied atrau-
matically to the vagina (M and VMgroups) 1 h before a viral challenge.
SHIV162P3 was added in a 1-ml volume containing 0.5 50% animal infec-
tive dose of an in vivo-titrated stock of the R5 virus SHIV162P3 (15), de-
rived from the HIV-1 SF162 primary isolate and propagated in phytohe-
magglutin-activated rhesus macaque peripheral blood mononuclear cells
(PBMC). Stock was obtained through the AIDS Research and Refer-
ence Reagent Program, Division of AIDS, National Institute of Allergy
and Infectious Diseases, NIH (catalog no. 6526) (contributors: Janet
Harouse, Cecilia Cheng-Mayer, and Ranajit Pal). Monkeys were bled
weekly for viral load determination, and infection status was deter-
mined by measuring plasma viral loads with a reverse transcription
(RT)-PCR assay with a sensitivity limit of 60 RNA copies/ml and a
quantification limit of 300 RNA copies/ml (16). No further vaginal
treatments were performed after the detection of viremia. Animals
were monitored to determine set point viral loads. We excluded ma-
caque 25015 from the M group because, at autopsy 2 months postin-
fection, we found a malformation of the genital tract, i.e., direct con-
nection of the vagina, uterus, and peritoneal cavity. We also excluded
animal 28413 from theM group because of a technical failure to deliver
the full dose in a viral challenge. A schematic representation of the
vaccination schedule, vaccination groups, and immunizations in parts
1 and 2 is shown in Fig. 1A.
Immunogenicity antibody analysis. TV-1- and SF162-specific bind-
ing antibodies were analyzed in serum and mucosal secretions. Briefly,
96-well plates were coated with a 1:1 ratio of anti-human  and  anti-
bodies (Southern Biotech) to capture the standard curves (IgG or IgA
standards) and TV1 and SF162 protein (1 g/ml) to capture antigen-
specific antibodies. Negative controls consisted of normal cynomolgus
macaque serum and assay buffer. Standard curves of IgG and IgA con-
sisted of 5-fold serial dilutions of purified IgG and IgA (starting at 1 g/
ml), and macaque serum andmucosal secretion samples were “screened”
at 1:100 and 1:10, respectively, with samples and controls added in tripli-
cate. Bound IgG was detected with goat anti-monkey IgG (Fc-specific)
horseradish peroxidase (HRP) conjugate (Serotec), and bound IgA was
detected with goat anti-monkey IgA (-chain-specific) HRP conjugate
(Autogen Bioclear). Following secondary antibody addition and develop-
ment, plates were read at 450 nm. Positive responses were determined
according to predefined cutoff values. Positive samples were titrated, and
concentrations were determined by extrapolation of unknown samples
against standards and expressed in micrograms of specific IgG or IgA per
milliliter.
Peptide array serum specificitymapping. Serum epitopemapping of
heterologous strains was performed essentially as previously described
(17, 18). Briefly, a peptide library of overlapping peptides (15-mers over-
FIG 2 Vaginal binding antibody responses in the VM group only postim-
munization prior to a challenge. Antibody responses weremeasured in vaginal
secretion samples collected after i.n. immunization (Post IN) at week 12 and
after i.m. immunization (Post IM) at week 34 prior to a challenge. SF162- and
TV-1-specific IgG antibodies are represented by black symbols, and red sym-
bols show SF162- and TV-1-specific IgA responses. A short horizontal line
with error bars indicates the mean  the standard error of the mean of each
group.
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lapping by 12 amino acids), covering seven full-length HIV-1 gp160 Env
consensus sequences (clades A to D; groups M, CRF1, and CRF2) and six
vaccine and laboratory strain gp120 sequences (A244_1, TH023_1,
MN_B, 1086_C, TV1_C, and ZM651_C) was printed onto epoxy glass
slides (provided by JPT Peptide Technologies GmbH, Berlin, Germany).
Microarray binding was performed with the HS4800 Pro Hybridization
Station (Tecan, Männedorf, Switzerland). All arrays were blocked with
Superblock T20 phosphate-buffered saline (PBS) blocking buffer for 0.5 h
at 30°C, followed by a 2-h incubation at 30°C with heat-inactivated
plasmadiluted 1:250 in SuperblockT20. Arrayswere incubated for 45min
at 30°C with goat anti-human IgG conjugated with DyLight649 (1.5-
g/ml final concentration; catalog no. 109-495-098; Jackson ImmunoRe-
search, West Grove, PA) diluted with Superblock T20. Washing between
steps was done with PBS containing 0.1% Tween. Arrays were scanned at
a wavelength of 635 nm with an Axon GenePix 4300 Scanner (Molecular
Devices, Sunnyvale, CA) at a photomultiplier setting of 540 and 100%
laser power. Images were analyzed with GenePix Pro 7 software (Molec-
ular Devices). The intensity of postimmunization serum binding to each
peptide was corrected with its own background value, which was defined
as the median signal intensity of the prebleed serum for that peptide plus
3 times the standard error of the three subarray replicates present on each
slide.
Neutralization TZM-bl assay. Viral titration and neutralization as-
sayswere performed as previously described (19, 20). Pseudotyped viruses
(PSVs) pCAGGSSF162gp160, BX08, 93MW965.26, TV1.21, TV1.29,
QH0692, DJ263.8, and pSV7d-SHIVSF162-Qlc32 4014; the infectious
molecular clone (IMC) pNL-LucR.T2A-SHIV162P3.5.ecto; and the cul-
ture supernatant of SHIV162P3M623-Derived were used. The JC53bl-13
(TZM-bl) cell line (catalog no. 5011) was obtained from the National
Institute for Biological Standards and Control (NIBSC) Center for AIDS
Reagents, United Kingdom, and validated as mycoplasma free with My-
coAlert (Lonza). Four 3-fold dilutions, startingwith 1/20 of each serumor
mucosal sample, were incubated with virus supernatant (200 tissue cul-
ture infective doses) for 1 h. Thereafter, 104 TZM-bl cells were added, the
plates were incubated for 48 h, and then luciferase activity was measured.
The positive controls were sera of HIV-1-infected individuals or ma-
FIG3 Mapping of serum IgGbinding to gp120 linear epitopes by peptidemicroarray. (A, B)Representative plots of gp120 binding in the serumof an immunized
animal binding to either consensus gp120 sequences or vaccine strain gp120 at the serum IgG response peak (2 weeks after the last immunization). The values on
the x axis are peptide numbers in the array library. Those on the y axis are signal intensities (baseline subtracted). Differently colored bars represent the different
strains/clades indicated. The variable (V) and constant (C) domains of gp120 are labeled in each panel. (C) Intensity of binding to each epitope identified in the
animals. The definition of each epitope as the range of peptide numbers in the array library is listed under each epitope. Color coding highlights higher intensity
in darker red. The pie chart shows the average binding to each epitope as a percentage of the total. Each pie slice represents the mean value for all of the animals
of maximum binding to the specified epitope/sum of maximum binding of all of the epitopes.
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caques and monoclonal antibodies known to neutralize the viruses. The
neutralization titer was defined as the sample dilution at which the num-
ber of relative luminescence units (RLU) was 50% of the number of RLU
in virus control wells after subtraction of the background number of RLU
in control wells with only cells.
ADCC activity. Antibody-dependent cell-mediated cytotoxicity
(ADCC) was tested as previously described (21), with the IMC pNL-
LucR.T2A-SHIV162P3.5.ecto. IMC-infected CEM.NKR.CCR5 cells
(obtained from the NIBSC Center for AIDS Reagents, United King-
dom [catalog no. 0099], and validated as mycoplasma free with Myco-
Alert [Lonza]) were incubated at a 1:30 ratio with PBMC and six 4-fold
dilutions of each serum starting with a 1:100 dilution. The percentages
of cells positive for the GzB substrate are reported as percentages
of granzyme B activity. The positive control was monoclonal anti-
body b12.
IFN- and IL-2 T-cell ELISpot assay. Enzyme-linked immunosor-
bent spot (ELISpot) assays were performed with MultiScreen 96-well fil-
tration plates (Millipore, Guyancourt, France) coated overnight at 4°C
with a monoclonal antibody against monkey gamma interferon (IFN-	;
clone GZ-4; Mabtech, Nacka, Sweden) and interleukin-2 (IL-2; CT-611
kit; U-Cytech Biosciences, Utrecht, The Netherlands) in accordance with
the manufacturer’s instructions. The plates were washed five times with
PBS and then blocked by incubation for 1 h at 37°C with RPMI 1640
medium containing glutamax-1 (Gibco, Life Technologies, United King-
dom) supplemented with 10% heat-inactivated fetal calf serum (FCS;
Lonza) (culture medium). Freshly isolated PBMC (2
 105 per well) were
stimulated in duplicate at 2 g/ml with an HIV-1 gp120 SF162 recombi-
nant protein (batchMID167d; Novartis) or with SIVmac251 Gag peptide
pools (15-mers overlapping by 11 amino acids). Control wells (103
PBMC) were stimulated with medium alone or with a phorbol myristate
acetate (1 g/ml). The plates were incubated for 24 h (gp120 glycopro-
tein) or 18 h (Gag peptide pools) at 37°C in a 5% CO2 atmosphere. They
were then washed five times with PBS. A biotinylated anti-IFN-	 (clone
7-B6-1; Mabtech) or anti-IL-2 (CT-611 kit; U-Cytech Biosciences) anti-
body was then added at a concentration of 1 g/ml in 0.5% FCS in PBS,
and the plates were incubated overnight at 4°C. The plates were then
washed five times with PBS, incubated with 0.25g/ml alkaline phospha-
tase-streptavidin conjugate (Sigma-Aldrich, St-Quentin Fallavier,
France) for 1 h at 37°C, and washed five times with PBS. Spots were
developed by adding nitroblue tetrazolium–5-bromo-4-chloro-3-in-
dolylphosphate substrate (Sigma-Aldrich) and counted with an auto-
mated ELISpot assay reader (ELR04XL; AutoimmunDiagnostikaGmbH,
Strassberg, Germany).
Statistical analyses.A time-to-event analysis was conducted with first
Kaplan-Meier estimates by using log rank tests comparing groups for data
sets in phase A and data sets in phase B.We then used a logisticmodel with
random effects taking into account repeated measurements of each ma-
caque. This type ofmodel allows the discrete exposure to the infection due
to the challenges at given times to be taken into account. Preliminary
analyses showed that the variance of the random effect was not signifi-
cantly different from zero (P 0.25), indicating little response variability
between monkeys. The first analysis of interest was logit(Pinfection 1)
0  1t  2G, where t represents the time since vaccination and G
represents the treatment group. The timeof infectionwas taken as the date
of the previous challenge prior to the first SIV-positive test result. How-
ever, sensitivity analysis, taking the time of infection as the previous chal-
lenge or before the previous challenge, did not change the results qualita-
tively (results not shown). The rationale of including t in the regression is
to take into account any residual confounding associated with a change in
the probability of infection over time. This could be due to the selection of
FIG 4 Neutralizing antibody titers of groups VMand V. (A to C) Kinetics of neutralizing response after each immunization in the VM (A, B) and the V (C)
groups. Sera were tested against PSV SF162 or 93MW965.26 in a TZM-bl assay. Dotted lines represent vaccinations at weeks 0, 4, 8 (i.n. immunizations with
R848), 16, and 28 (i.m. immunizations with MF59). (D) Neutralizing antibody titers of NHP in the VM group 30 weeks after the first immunization against
a panel of PSVs of tiers 1 and 2 in a TZM-bl assay. Solid horizontal lines in panel D indicate mean neutralizing titers.
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the population, those being the most resistant being uninfected until the
end. This analysis was run on the data set of parts 1 and 2. We then
extended the analysis by dissociating the effects of vaccination (V) and
microbicide (M) and their interaction (V ·M) as follows: logit(Pinfection
1) 0 1t 2V 4V · M. Second-order interactions among M,
V, and t were tested but were not significant (P 0.91). However, in the
final analysis, we used logit(Pinfection 1)01tp22V3M
4V · tp25V ·M. Time (t) was categorized as an indicator of part 1 or 2,
tp2  I (t  22weeks), and the effect of the interaction V · tp2 was kept
(P  0.22). Results were used to compare the effects of VM in parts 1
and 2. This analysis was run on the pooled data set of parts 1 and 2. All
results are reported as odds ratios (ORs) together with their 95% con-
fidence intervals (CIs) and P values for statistical significance. Results
are presented as percentages of risk reduction, but it should be kept in
mind that ORs are only approximations of risk estimates. We com-
pared the results of logistic regression with the time-to-event Cox
model analysis results. Hazard ratios and ORs give similar conclu-
sions (results not shown). Analyses were run with R software and the
packages “survival” for survival and “lme4” for logistic mixed-effect
models.
RESULTS
Study design. In this study, we use an NHP model to determine
potential interactions of combining a microbicide with an enve-
lope-based vaccine over either intervention alone. We chose to
study vaginal transmission, as most vaccine and microbicide effi-
cacy trials will likely be dependent upon the use of trial sites in
sub-Saharan Africa, where the infection rates are highest among
FIG 5 Time-to-event survival analysis Kaplan-Meier curves and infection of macaques determined by RT-PCR in plasma. Groups: V, vaccine alone; VM,
vaccine plus microbicide; M, microbicide alone; C, control. (A) Kaplan-Meier plots of animals confirmed infected by RT-PCR. Red, control animals; purple, V
group; blue, VM group; green, M group. (B) Plasma viral loads of individual macaques during challenge phases. Vertical dotted lines indicate the dates of
challenges; horizontal lines indicate the limit of quantification (300 copies/ml).
TABLE 1 OR for group effects on the probability of infection in part 1a
Group effect OR 95% CI P value
Intercept 0.22 0.09, 0.53 0.001
Time 0.94 0.87, 1.00 0.077
VM vs C 0.21 0.06, 0.71 0.013
M vs C 0.55 0.20, 1.56 0.263
V vs C 1.73 0.56, 5.32 0.341
a Reference: group C.
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women (22).We chose to evaluate a 1% tenofovir microbicide gel
on the basis of its reported efficacy in the CAPRISA 004 trial (5).
We focused on an HIV-1 envelope-based vaccine, reflecting the
likely protective role of antibody in RV144, and adopted a vaccine
strategy previously shown to protect NHPs against a vaginal chal-
lenge with tier 1 SHIVSF162p4 (23). We designed a two-part study
to test the potential interactions (positive or negative) between
these two biomedical strategies over single interventions. In part
1, we compared the protective efficacies of the envelope-based
vaccine (V group), 1%microbicide tenofovir gel alone (Mgroup),
and their combination (VM group) against 12 repeat vaginal
challenges with the tier 2 SHIV strain SF162P3 (SHIVSF162p3) (Fig.
1A). Critical to the experimental design was that neither of the
individual interventions could be fully protective by itself; there-
fore, we elected to use SHIVSF162p3 rather than more closely
matched strain SHIVSF162p4, against which vaccination was previ-
ously shown to provide 100%protection (23). In part 2, protected
animals were challenged a further 12 times in the absence of mi-
crobicide.
Vaccination and vaginal SHIV challenge. Cynomolgus ma-
caques in the vaccine groups (V and VMgroups) received three
i.n. priming immunizations (0, 4, and 8 weeks) with a combina-
tion of two gp140 uncleaved trimers (TV-1 clade C plus SF162
clade B) coadministered with R848 (TLR7/8) adjuvant, followed
by two i.m. boost immunizations (16 and 28weeks) deliveredwith
MF59 adjuvant. This induced robust serum binding antibody re-
sponses (IgG and IgA) to both immunogens (TV-1 and SF162
gp140) that remained stable through to week 39, the start of the
challenge (Fig. 1B to E). Weak vaginal responses were observed in
some animals after i.n. priming, and they were boosted following
i.m. immunization (Fig. 2). Peptide array analysis demonstrated
that all of the animals developed a strong cross-clade anti-V3 re-
sponse and responses to the gp41 immunodominant region. An-
imals also developed cross-clade responses of lower intensity to
V2, C2, and C5 gp120 epitopes (Fig. 3). Autologous serum neu-
tralizing antibodies to HIV-1 SF162 were induced following i.m.
boosts (7,891  11,728 [mean  standard deviation]) that de-
creased by approximately 1 log prior to a challenge (Fig. 4A).
Neutralizing antibodies were absent from vaginal secretions or
below the level of detection. Serum neutralizing antibody re-
sponses to clade C 93MW965.26 (1,757  2,240) were also in-
duced by week 30, but those to TV1 or tier 2 viruses of other
subtypes were not (Fig. 4B and D). As similar responses had been
fully protective against tier 1 SHIVSF162p4 (23), we elected to use
the variant SHIVSF162p3, which differs by 22 amino acids and con-
tains an additional glycan at the N-terminal base of the V2 loop
predicted to confer escape from autologous neutralization (24).
Prechallenge sera and vaginal samples were confirmed to have
little or no neutralizing activity against SHIVSF162p3 (Fig. 4C). As
predicted on the basis of neutralization, the vaccine alone (group
V) did not protect against 12 consecutive low-dose intravaginal
challenges with SHIVSF162P3 (Fig. 5A and Table 1), where 50% of
the animals in both the V and naive control (C) groups became
infected after two challenges (Table 2). Strikingly, there were
more infections in the V group than in the C group, with an OR
of 1.73, although this did not reach statistical significance (P
0.341; Table 1), and the baseline risk of infection in the V group
was almost double that in the C group (Table 2). Furthermore,
the vaccine alone had no impact on viral load kinetics or con-
trol (Fig. 5B).
Tenofovir gel and vaginal SHIV challenge. The microbicide
regime was designed to be partially protective; in our study, 1%
tenofovir gel was applied vaginally 1 h before each of 12 sequential
vaginal challenges. We confirmed in cynomolgus macaques that
TABLE 2 Summary analysis of infection risk in part 1
Animal
group
No. of protected
animals/total
% of protected
animals
No. of
challenges
No. of challenges to infect
50% of animals (95% CI) P valuea HR (95% CI)b
Baseline risk
of infection
C 4/12 33 12 2.0 (1.0, undetermined) 0.087
V 1/8 13 12 2.0 (2.0, undetermined) 0.568 1.53 (0.55, 4.26) 0.159
M 6/14 43 12 9.5 (5.0, undetermined) 0.272 0.56 (0.21, 1.49) 0.068
a Versus group C (Mantel-Cox test) overall, P 0.00.
b HR, hazard ratio; Cox model for time to infection.
TABLE 3 Pharmacokinetics of vaginally applied 1% tenofovir gela
Drug and
location
Mean Cmax
b (ng/g)
 SD Tmax
c (h)
Mean AUC0–12
d
(ng · h/g) SD
TDF
Serum 349 196 1 793 388
Vagina 151,533 89,312 1 877,034 133,061
Exocervix 286,960 169,805 1 756,546 277,502
Endocervix 39,472 29,670 1 98,139 36,024
Uterus 14,449 6,068 1 38,967 13,847
TDF-DP
Vagina 94 4 4 668 142
Exocervix 64 16 4 883 571
Endocervix 10
Uterus 10
a The pharmacokinetics of TDF and TDF diphosphate (TDF-DP) in female genital tract
tissues and serum after intravaginal administration of 1% tenofovir gel were
determined. Tissues were sampled at necropsy (two animals per time point), which
was performed at 0, 1, 4, or 12 h after gel administration. Tenofovir was quantified
in serum by high-performance liquid chromatography–tandem mass spectrometry.
Lower limits of quantification: 10 ng/g in vaginal, exocervical, and uterine tissues
and 25 ng/g in endocervical tissue. TDF-DP in serum was quantified by high-
performance liquid chromatography–tandem mass spectrometry. The lower limit of
quantification was 10 ng.
b Cmax, maximum concentration of drug in serum.
c Tmax, time to Cmax.
d AUC0–12, area under the concentration-time curve from 0 to 12 h.
TABLE 4 OR for group effects on the probability of infection in part 2a
Group effect OR 95% CI P value
Intercept 0.38 0.15, 0.95 0.039
Time 0.94 0.87, 1.01 0.077
VM vs V 0.12 0.03, 0.44 0.001
M vs V 0.32 0.11, 0.98 0.045
C vs V 0.58 0.19, 1.78 0.341
a Reference: group V.
Superior Efﬁcacy of Combined Vaccine and Microbicide
June 2016 Volume 90 Number 11 jvi.asm.org 5321Journal of Virology
 o
n
 M
ay 17, 2016 by Im
perial College London
http://jvi.asm.org/
D
ow
nloaded from
 
tenofovir disoproxil fumarate (TDF) levels measured in periph-
eral blood and genital tissue at different time points following 1%
tenofovir gel application reached concentrations compatible with
local antiviral activity (Table 3). We also measured TDF diphos-
phate in genital tissues as a means to quantify the active drug
phosphorylated by local exposed cells. In both cases, levels similar
to those reported in rhesus macaques (25) and in humans in the
CAPRISA 004 trial were observed (26). To limit the number of
animals included in this study (50 in total), we assumed the risk of
not detecting a benefit of the partially effective microbicide alone
(group M) relative to naive animals (group C). This was indeed
the case compared to naive controls (OR, 0.55; P  0.263; Table
1).However, on the basis of theKaplan-Meier curves (Fig. 5A), 9.5
challenges would be required to infect 50% of the animals in
group M, compared to 2 challenges for those in groups C and V
(Table 2). Themicrobicide alone provided a 68% reduction in the
risk of infection relative to that of the vaccine group (OR, 0.32;
P  0.045; Table 4). There was, however, no apparent impact of
tenofovir gel on viral load kinetics in animals that became infected
(Fig. 5B).
Vaccine-microbicide combination provides enhanced pro-
tection. As the primary objective was to assess the potential ben-
efit of applying the vaginal microbicide approach to previously
vaccinated animals, this study was designed to determine the effi-
cacy of the combination (VM group, n 16) and that of either
intervention alone. VM group animals were vaccinated in par-
allel with group V, and challenge studies commenced at week 39.
In these animals, the microbicide was applied in an identical fash-
ion to that used for groupM in each of the 12 challenges in part 1
(Fig. 1A). The VM combination provided a 79% reduction in
the per-exposure probability of infection (P  0.013; Table 4)
relative to that of naive controls, an 88% reduction (OR, 0.12; P
0.001; Table 1) relative to vaccine alone and a 63% reduction (OR,
0.39) relative to microbicide alone, although this did not reach
statistical significance (P  0.114) (Fig. 5A). Only four animals
were infected after 12 repetitive challenges, too few to predict the
number of challenges needed to reach 50% infection in the VM
group. Animals that remained uninfected following 12 consecu-
tive intravaginal challenges in the presence of microbicide (chal-
lenge part 1) immediately progressed to challenge part 2 (Fig. 1A).
Here, all protected animals received a further 12 sequential chal-
lenges, irrespective of their initial assignment to the M (n 6) or
VM (n 12) group, to determine susceptibility in the absence
of microbicide. By the end of part 2 (Fig. 5A) there was still no
statistically significant difference between groupM and untreated
controls in part 1 (Table 5), while in the VMgroup, there was an
84% reduction in the per-exposure probability of infection (P 
0.010) relative to that of untreated controls and an 86% reduction
in the per-exposure probability of infection relative to that of vac-
cine alone (P 0.002). Here, the positive interaction between the
microbicide and the vaccine remained the same (interaction co-
efficient P 0.13). In order to gain further insight, we discretized
the time into parts 1 and 2 and reran the analysis. This analysis
indicated that themicrobicide alone over the entire course of parts
1 and 2 showed a trend toward protection (OR, 0.26 [0.06:1.02];
P  0.054; Table 6), whereas the microbicide and vaccine com-
bined provided significant protection, with a 91% reduction in the
per-exposure probability of infection (P  0.004; Table 6). Fur-
ther analysis was performed to investigate the potential interac-
tion between time and vaccination in theVMgroup (discretized
in parts 1 and 2). The effect of the VM group compared to the
control increased in part 2, providing a 98%(P 0.002) reduction
in the per-exposure probability of infection in part 2 compared to
89% (P 0.010) in part 1, indicating a long-term effect of vacci-
nation even without the microbicide (Table 7). We excluded po-
tential confounders that might have influenced differences in
susceptibility. The distribution of theMHC genotype was equal
across the different groups (13). Furthermore, recent studies
demonstrated that the TRIM5 genotype has very little vari-
ability in Mauritian cynomolgus macaques and has no impact
on virus acquisition or vaccination outcome (14). To more
faithfully replicate the human condition, animals were not
treated with Depo-Provera, which is often used to enhance
susceptibility to infection. All of the animals were naturally
cycling. Analysis of progesterone levels showed no overrepre-
sentation in any group of animals in the follicular phase, asso-
ciated with heightened susceptibility.
Immuneparametersmodulatedbyprotected exposure to in-
fectious SHIV. Subsequently, we assessed potential immune pa-
rameters thatmight be associated with enhanced protection in the
VM group relative to that in the V or M group. Prior to a chal-
lenge, the serum or mucosal antibody titers in the V and VM
groups were similar although the serum antibody titers were
slightly raised in the V-only group (P 0.0045, Fig. 6A and 1B to
D). Titers of induced serum binding antibodies to SF162 and
TABLE 5 OR for treatment type on the probability of infection in parts
1 and 2 combined
Group effect OR 95% CI P value
Intercept 0.23 0.11, 0.47 0.001
Time 0.95 0.92, 0.98 0.004
V vs C 1.17 0.49, 2.82 0.720
M vs C 0.46 0.18, 1.20 0.113
VM vs C 0.16 0.04, 0.65 0.010
VM vs V 0.14 0.04, 0.50 0.002
TABLE 6 OR for treatment type on the probability of infection in parts
1 and 2 combineda
Group effect OR 95% CI P value
Intercept 0.22 0.09, 0.57 0.001
Time in phase B 0.35 0.10, 1.19 0.093
V vs C 0.97 0.28, 3.28 0.958
M vs C 0.26 0.06, 1.02 0.054
VM vs C 0.09 0.02, 0.46 0.004
VM vs V 0.09 0.02, 0.45 0.003
a Discretized time.
TABLE 7 OR for treatment type on the probability of infection in parts
1 and 2 combined depending on timea
Group effect OR 95% CI P value
Intercept 0.17 0.06, 0.47 0.001
Time in phase B 0.75 0.14, 4.09 0.738
V vs C 1.91 0.39, 9.28 0.425
M vs C 0.37 0.09, 1.59 0.185
VM in phase A vs C 0.11 0.02, 0.59 0.010
VM in phase B vs C 0.02 0.001, 0.22 0.002
a Interaction of order 2 vaccine by microbicide by time.
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TV-1 gp140 were high prechallenge and may have masked any
potential boosting effects of protected exposure in the VM
group (Fig. 1B).However, therewas no evidence of boosting in the
mucosal samples of protected animals over time. There was little
or noneutralization of SHIVSF162P3 in serumandmucosal samples
prior to a challenge in both theV andVMgroups (Fig. 4) and no
evidence of an induced response in protected animals at any point
during parts 1 and 2. However, autologous neutralizing responses
to HIV-1SF162 were equivalent in the VMgroup relative to the V
group prior to a challenge and postimmunization (Fig. 7A), with
no evidence of boosting in protected animals after 6, 9, or 12
challenges in part 1 (Fig. 7B to E) or change in epitope recognition
assessed by peptide array analysis (data not shown). In addition,
there was no evidence of boosting of neutralizing responses to
HIV-1SF162 or 93MW965.26 in protected animals in part 1 in the
presence of microbicide or in part 2 in the absence of microbicide
(Fig. 8). Furthermore, ADCC responses to SHIVSF162P3 were ab-
sent from all of the uninfected animals at all of the time points
examined.
Robust cellular immune responses to SF162 gp120 were de-
tected by ELISpot assay in the V and VM groups after the five
immunizations. Responses were similar in both groups Fig. 9,
with mean numbers of spot-forming cells per million PBMC of
369 246 and 274 171 for IFN-	 and IL-2, respectively (Fig. 9A
and B). There was no correlation between prechallenge vaccine-
induced IFN-	 and IL-2 gp120-specific responses and protection
observed after challenges in parts 1 and 2.We alsomeasuredT-cell
responses to gp120 stimulation after the first sequence of chal-
lenges. These had significantly decreased in group V compared to
prechallenge measurements in week 34 (P  0.0058 and P 
0.0002 for IFN-	 and IL-2, respectively, Fig. 9C and D), down to
the level of control animals (groupC). The responses of repeatedly
exposed nonvaccinated animals in group M were similar (P 
0.7315 and P 0.9027 for IFN-	 and IL-2, respectively) to those
of control animals (group C), indicating no added benefit for na-
ive animals when they were exposed to the virus in the presence of
microbicide.
Remarkably, the responses of vaccinated animals appeared
to be significantly increased when they were exposed to
SHIVSF162P3 following treatment with TDF gel (VM group)
in comparison to those of animals in groups V (P 0.0058 and
P  0.0002 for IFN-	 and IL-2) and M (P  0.0001 and P 
0.0001 for IFN-	 and IL-2), demonstrating that repeated chal-
lenges of preimmunized animals when using microbicides for
prevention evoke exposure-induced immunity. However, re-
sponses raised in protected animals in this group were similar
to those of nonprotected macaques. All of the animals infected
in parts 1 and 2 demonstrated robust responses to SIV Gag
peptide pools, irrespective of the intervention group (Fig. 9G
and H); however, there were no detectable anti-Gag responses
in any of the protected animals following sequential challenges
in parts 1 and 2, irrespective of the intervention group (M or
VM).
FIG 6 Vaccine-induced binding antibodies to SF162 in serum. Groups: V, vaccine alone; VM, vaccine plus microbicide; M, microbicide alone; C, control. (A
toD) Serum response antibody levels in nanograms permilliliter prechallenge at week 34 (A), after 6 challenges (B), after 9 challenges (C), and after 12 challenges
(D). Colors are indicative of the time at which infection was detected by plasma viremia as follows: red, during the first 6 challenges (until week 9 postchallenge);
blue, during challenges 7 to 12 (weeks 11 to 21 postchallenge); black, during challenges 13 to 24 (from week 22, in the absence of microbicide). Empty symbols
represent animals that did not show signs of infection.
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FIG 7 Titers of neutralizing antibodies to SF162 in serum. Sera were analyzed by TZM-bl assay at 12 weeks after i.n. immunization and at 34 weeks after i.m.
immunization (A), prechallenge (B), after 6 challenges (C), after 9 challenges (D), and after 12 challenges (E). Each symbol represents one animal, and colors are
indicative of the times when infection was detected by plasma viremia as follows: red, during the first 6 challenges (up to 9 weeks postchallenge); blue, challenges
7 to 12 (weeks 11 to 21 postchallenge); black, challenges 13 to 24. Empty symbols represent animals that were not infected. There was no statistically significant
difference between the V and VM groups at any point.
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DISCUSSION
The primary aim of this study was to determine any potential
superiority of a microbicide-vaccine combination to single pre-
vention approaches. The lack of protection by the vaccine alone
and lack of virologic control upon a challenge with the tier 2
autologous escape variant SHIVSF162p3 is unsurprising. This
contrasts with the earlier observation of protection against a
high-dose challenge with SF162 immunogen-matched tier 1
SHIVSF162p4 (23). These data reflect the dominant role of neutral-
izing antibodies in sterilizing protection, while the absence of in-
duced ADCC activity likely accounts for the lack of impact on
virologic control. However, the observation that 7/8 animals were
infected in the vaccine group versus 4/12 in the control group,
although not statistically significant, is troubling, given the poten-
tial for vaccination to increase the risk of acquisition in large-
cohort studies (11, 12). Interestingly, the observed level of protec-
tion (43%) in the M group closely matched that reported for
women who were highly compliant with the dosing regime in
CAPRISA 004 (5), although in our study with a limited number of
animals, this did not reach statistical significance. Gel alone had
no impact on viral kinetics; thus, at the systemic level, therewas no
evidence that the microbicide delayed or blunted infection. In-
deed, while protection appeared to be an all-or-nothing event, the
per-exposure probability of infection was reduced by 68% relative
to that of the vaccine group, with a predicted per-exposure risk of
infection of 0.068 relative to 0.087 for controls or 0.159 for the
vaccine-only group (Table 2). Interestingly, there was no evidence
of seroconversion in exposed but protected animals in the M
group, despite repeated viral challenges (Fig. 5). These data are in
accord with previous studies of humans and macaques where re-
peat vaginal exposure to 500 g of recombinant gp140 failed to
induce antibody responses (27, 28). The observed lack of serocon-
version is in contrast to the reported seroconversion of a small
number of subjects in the CAPRISA 004 trial (29) but is in accor-
dancewith the report on the Partners PrEP study (30). It is unclear
if induced antibody responses in CAPRISA 004 were dependent
upon limited replication that was insufficient to establish infec-
tion.
The VM combination was the only group to show a statisti-
cally significant difference from the naive controls and the V-only
group. Thus, any potential vaccine-related enhancement in the
per-exposure risk of infection was mitigated by the VM combi-
nation. Furthermore, there was a 63% risk reduction (OR, 0.39) in
the VM group relative to that of M alone, although this did not
reach statistical significance. Nevertheless, the Kaplan-Meier
curves frompart 1 predict that 9.5 challenges would be required to
infect 50% of the animals in group M, while too few animals (4/
16) were infected in the VMgroup to reliably calculate the same
estimation for the combination group. Larger studies are needed
to confirmor refute a difference between the VMandMgroups.
However, the positive interaction between the microbicide and
the vaccine appeared to have a sustained effect in part 2, where
animals were challenged in the absence of a microbicide (interac-
tion coefficient P  0.13). This long-term benefit may indicate a
durable effect of vaccination in this group or reflect the fact that
repetitive challenges select animals with higher or increasing re-
sistance to infection over time. The only observable impact of
protected viral exposure on vaccine-induced immunity in the
VM group was an increased cellular response to Env relative to
that of the V group after six repetitive challenges. The significance
of this finding is unclear, as the level of cellular responses was not
predictive of resistance to infection. Nevertheless, this echoes
studies with the rhesus cytomegalovirus vector encoding SIVGag,
Rev-Tat-Nef, and Env that protected 50% of the animals from
productive infection despite inducing equivalent cell-mediated
immune responses in protected and unprotected animals (31). In
contrast, antibody levels were too high to ascertain any boost ef-
fects of protected exposure in the VMgroup. Irrespective of the
mechanism, the persistent positive impact of the VM combina-
tion is encouraging.
Previous studies of NHP have suggested a potential benefit of
combining T-cell-based vaccine approaches with vaginal micro-
bicides; however, sample sizes were small and the microbicide
approaches used have yet to be tested in human efficacy studies
(32, 33). This study is the first to assess the potential benefit of
combining amicrobicidewith a humoral vaccine.We believe that
our data suggest that a microbicide-vaccine combination
might provide greater efficacy than either intervention alone.
The observed benefits are likely to be improved with a vaccine
that contains optimal B- and T-cell immunogens. Perhaps
more importantly, these data indicate that provision of ARV
prophylaxis ameliorates the potential for a vaccine-associated
increased risk of infection. Although we assessed the efficacy of
tenofovir gel, the protective effects would likely be similar or
greater with oral prophylaxis, where compliance levels may be
more reliable (34). This has important implications given that
oral PrEP could be adopted as the baseline intervention for
future HIV/AIDS vaccine trials. Our findings are contempora-
neous with plans to evaluate a regimen similar to that of
RV144, a partially effective vaccine thought to be mediated by
humoral immunity in the absence of tier 2 neutralization, in
South Africans (35, 36). This has important implications, given
that oral PrEP could be adopted as the baseline intervention for
future HIV/AIDS vaccine trials.
FIG 8 Neutralizing antibody responses to SF162 during challenge phase parts
1 and 2. TZM-bl assay neutralization data 5 weeks before a challenge (0 wk); 9,
17, and 21 weeks after the first challenge with microbicide; 1 week after the 12
challenges without microbicide (week 42); and 5 weeks thereafter (week 47).
Each symbol represents one animal. Colors are indicative of the times when
infection was detected by plasma viremia as follows: red, during the first 6
challenges (until week 9 postchallenge); blue, during challenges 7 to 12 (weeks
11 to 21 postchallenge); black, during challenges 13 to 24 (fromweek 22, in the
absence of microbicide). Empty symbols represent animals that were not in-
fected. Themean of each group is indicated by a solid line. For VMversus V,
P 0.0001 (Mann-Whitney test).
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FIG 9 T-cell responses measured by ELISpot assay pre- and postchallenge. gp120-specific T-cell ELISpot assay responses in numbers of spot-forming cells/106
PBMC prechallenge (A, B) and after six challenges (C, D) and SIV Gag-specific T-cell ELISpot assay responses prechallenge (E, F) and after six challenges (G, H)
are shown. Red symbols indicate infection during the first six challenges, blue symbols indicate infection during challenges 7 to 12 (weeks 11 to 21 postchallenge),
and black symbols indicate infection during challenges 13 to 24. Empty symbols represent animals that were not infected. Solid lines indicate mean values. P
values, where relevant following statistical analysis, are also shown.
Le Grand et al.
5326 jvi.asm.org June 2016 Volume 90 Number 11Journal of Virology
 o
n
 M
ay 17, 2016 by Im
perial College London
http://jvi.asm.org/
D
ow
nloaded from
 
ACKNOWLEDGMENTS
Particular thanks to Gustavo Doncel for discussion of the study plan
and provision of tenofovir gel through CONRAD. Special thanks to
Rino Rappuoli for his outstanding coordination and support of all of
the EUROPRISE Consortium’s activities. We are very thankful for the
excellent technical assistance of the staff of the TIPIV lab and the
animal facilities at the IDMIT Center. We thank Justyna Czyzewska-
Khan and Nicola Hopewell for technical assistance. We also thank
Nancy Miller of the AIDS Research and Reference Reagent Program of
the NIH for assistance with SHIV challenge stock.
R.J.S., R.L.G., and G.S. designed the research studies. R.L.G., N.D.-B.,
S.D., L.G., D.D., X.S.,M.T., H.S., G.T.,M.P., A.C., andG.S. conducted the
experiments. R.L.G.,N.D.-B., L.G.,D.D., X.S., G.T.,M.P., A.C., G.S., R.T.,
and R.J.S. analyzed the data. C.O. and S.W.B. provided reagents. R.J.S.,
R.L.G., G.S., and A.C. wrote the manuscript.
SusanBarnett kindly provided the vaccineswith no conflict of interest.
We have no conflicts of interest to declare.
FUNDING INFORMATION
This work, including the efforts of Roger LeGrand, was funded by
EQUIPEX (ANR-10-EQPX-02-01). This work, including the efforts of
Susan Barnett, was funded by HHS | NIH | National Institute of Allergy
and Infectious Diseases (NIAID) (5P01 AI066287). This work, including
the efforts of Robin J. Shattock, AletheaCope, and StefaniaDispinseri, was
funded by European Commission (EC) (LSHP-CT-2006-037611).
This study was supported by Equipements d’Excellence (EQUIPEX) 2010
FlowCyTech, funded by Programme Investissements d’Avenir under
grant agreement ANR-10-EQPX-02-01, and by Infrastructures Nation-
ales en Biologie et Santé (INBS) 2011 Infectious Disease Models and In-
novative Therapies (IDMIT), funded by Programme Investissements
d’Avenir under grant agreement ANR-11-INBS-0008. We thank the
Agence Nationale de Rercherche sur le SIDA et les Hépatitues Virales
(ANRS; France) for support provided for the implementation of the NHP
model used in this project. Reagent generation by C. Ochsenbauer was
supported by Bill &Melinda Gates Foundation-funded Collaboration for
AIDS Vaccine Discovery (CAVD)/CAVIMC grant 1032144 and by facili-
ties of the Virology Cores of the University of Alabama at Birmingham
Center for AIDS Research (CFAR) funded by CFAR grant P30-AI-27767.
The work at Novartis Vaccines was supported in part by NIAID.
REFERENCES
1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J,
Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M,
Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL,
Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Mi-
chael NL, Kunasol P, JHKim, Investigators MOPH-TAVEG. 2009.
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection
in Thailand. N Engl J Med 361:2209–2220. http://dx.doi.org/10.1056
/NEJMoa0908492.
2. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L,
Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich
ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP,
Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG,
Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, De-
fechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J,
Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV, iPrEx
Study Team. 2010. Preexposure chemoprophylaxis for HIV preven-
tion in men who have sex with men. N Engl J Med 363:2587–2599.
http://dx.doi.org/10.1056/NEJMoa1011205.
3. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J,
Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye
E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A,
Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka
C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK,
Kidoguchi L, Krows M, Revall J, Morrison S, Haugen MH, Emmanuel-
Ogier Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, Bumpus NN,
Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C, Partners
PrEP Study Team. 2012. Antiretroviral prophylaxis for HIV prevention
in heterosexual men and women. N Engl J Med 367:399–410. http://dx
.doi.org/10.1056/NEJMoa1108524.
4. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE,
Segolodi TM, Henderson FL, Pathak SR, Soud FA, Chillag KL, Mutan-
haurwa R, Chirwa LI, Kasonde M, Abebe D, Buliva E, Gvetadze RJ,
Johnson S, Sukalac T, Thomas VT, Hart C, Johnson JA, Malotte CK,
Hendrix CW, Brooks JT, TDF2 Study Group. 2012. Antiretroviral
preexposure prophylaxis for heterosexual HIV transmission in Botswana.
N Engl J Med 367:423–434. http://dx.doi.org/10.1056/NEJMoa1110711.
5. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C,
Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah
TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D,
CAPRISA 004 Trial Group. 2010. Effectiveness and safety of tenofovir
gel, an antiretroviral microbicide, for the prevention of HIV infection
in women. Science 329:1168–1174. http://dx.doi.org/10.1126/science
.1193748.
6. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. 2012.
Unraveling the divergent results of pre-exposure prophylaxis trials for
HIV prevention. AIDS 26:F13–F19. http://dx.doi.org/10.1097/QAD
.0b013e3283522272.
7. Hankins CA, de Zalduondo BO. 2010. Combination prevention: a
deeper understanding of effective HIV prevention. AIDS 24(Suppl 4):
S70–S80. http://dx.doi.org/10.1097/01.aids.0000390709.04255.fd.
8. Shattock RJ, Warren M, McCormack S, Hankins CA. 2011. AIDS.
Turning the tide against HIV. Science 333:42–43. http://dx.doi.org/10
.1126/science.1206399.
9. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, Ham C,
Heeney J, Rezk N, Kashuba A, Anton P, McGowan I, Shattock RR.
2008. Prevention of SIV rectal transmission and priming of T cell re-
sponses in macaques after local pre-exposure application of tenofovir gel.
PLoS Med 5:e157. http://dx.doi.org/10.1371/journal.pmed.0050157.
10. Kersh EN, Adams DR, Youngpairoj AS, Luo W, Zheng Q, Cong ME,
Aung W, Mitchell J, Otten R, Hendry RM, Heneine W, McNicholl J,
Garcia-Lerma JG. 2011. T cell chemo-vaccination effects after repeated
mucosal SHIV exposures and oral pre-exposure prophylaxis. PLoS One
6:e19295. http://dx.doi.org/10.1371/journal.pone.0019295.
11. Ondondo BO. 2014. The influence of delivery vectors on HIV vaccine
efficacy. Front Microbiol 5:439. http://dx.doi.org/10.3389/fmicb.2014
.00439.
12. Carnathan DG, Wetzel KS, Yu J, Lee ST, Johnson BA, Paiardini M, Yan
J, Morrow MP, Sardesai NY, Weiner DB, Ertl HC, Silvestri G. 2015.
Activated CD4 CCR5 T cells in the rectum predict increased SIV ac-
quisition in SIVGag/Tat-vaccinated rhesus macaques. Proc Natl Acad Sci
U S A 112:518–523. http://dx.doi.org/10.1073/pnas.1407466112.
13. Aarnink A, Dereuddre-Bosquet N, Vaslin B, Le Grand R, Winterton
P, Apoil PA, Blancher AA. 2011. Influence of the MHC genotype on
the progression of experimental SIV infection in the Mauritian cyno-
molgus macaque. Immunogenetics 63:267–274. http://dx.doi.org/10
.1007/s00251-010-0504-6.
14. Mattiuzzo G, Rose NJ, Almond N, Towers GJ, Berry N. 2013.
Up-regulation of TRIM5 gene expression after live-attenuated simian
immunodeficiency virus vaccination in Mauritian cynomolgus ma-
caques, but TRIM5 genotype has no impact on virus acquisition or
vaccination outcome. J Gen Virol 94:606–611. http://dx.doi.org/10
.1099/vir.0.047795-0.
15. Harouse JM, Gettie A, Eshetu T, Tan RC, Bohm R, Blanchard J, Baskin
G, Cheng-Mayer C. 2001. Mucosal transmission and induction of simian
AIDS by CCR5-specific simian/human immunodeficiency virus
SHIVSF162P3. J Virol 75:1990–1995. http://dx.doi.org/10.1128/JVI.75.4
.1990-1995.2001.
16. Dereuddre-Bosquet N, Morellato-Castillo L, Brouwers J, Augustijns P,
Bouchemal K, Ponchel G, Ramos OH, Herrera C, Stefanidou M, Shat-
tock R, Heyndrickx L, Vanham G, Kessler PR, Le Grand R, Martin L.
2012. MiniCD4 microbicide prevents HIV infection of human mucosal
explants and vaginal transmission of SHIV (162P3) in cynomolgus ma-
caques. PLoS Pathog 8:e1003071. http://dx.doi.org/10.1371/journal.ppat
.1003071.
17. Tomaras GD, Binley JM, Gray ES, Crooks ET, Osawa K, Moore PL,
Tumba N, Tong T, Shen X, Yates NL, Decker J, Wibmer CK, Gao F,
Alam SM, Easterbrook P, Abdool Karim S, Kamanga G, Crump JA,
Cohen M, Shaw GM, Mascola JR, Haynes BF, Montefiori DC, Morris L.
2011. Polyclonal B cell responses to conserved neutralization epitopes in a
Superior Efﬁcacy of Combined Vaccine and Microbicide
June 2016 Volume 90 Number 11 jvi.asm.org 5327Journal of Virology
 o
n
 M
ay 17, 2016 by Im
perial College London
http://jvi.asm.org/
D
ow
nloaded from
 
subset of HIV-1-infected individuals. J Virol 85:11502–11519. http://dx
.doi.org/10.1128/JVI.05363-11.
18. Schiffner T, Kong L, Duncan CJ, Back JW, Benschop JJ, Shen X, Huang
PS, Stewart-Jones GB, DeStefano J, Seaman MS, Tomaras GD, Monte-
fiori DC, Schief WR, Sattentau QJ. 2013. Immune focusing and en-
hanced neutralization induced by HIV-1 gp140 chemical cross-linking. J
Virol 87:10163–10172. http://dx.doi.org/10.1128/JVI.01161-13.
19. Sarzotti-Kelsoe M, Bailer RT, Turk E, Lin CL, Bilska M, Greene KM,
Gao H, Todd CA, Ozaki DA, Seaman MS, Mascola JR, Montefiori DC.
2014. Optimization and validation of the TZM-bl assay for standardized
assessments of neutralizing antibodies against HIV-1. J Immunol Meth-
ods 409:131–146. http://dx.doi.org/10.1016/j.jim.2013.11.022.
20. Heyndrickx LA, Heath A, Sheik-Khalil E, Alcami J, Bongertz V, Jansson
M, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis
V, Ramaswamy M, Sattentau Q, Tolazzi MH, Schuitemaker H, Willems
B, Wrin T, Fenyö EM, Scarlatti G. 2012. International network for
comparison of HIV neutralization assays: the NeutNet report II. PLoS
One 7:e36438. http://dx.doi.org/10.1371/journal.pone.0036438.
21. Pollara J, Hart L, Brewer F, Pickeral J, Packard BZ, Hoxie JA, Komoriya
A, Ochsenbauer C, Kappes JC, Roederer M, Huang Y, Weinhold KJ,
Tomaras GD, Haynes BF, Montefiori DC, Ferrari G. 2011. High-
throughput quantitative analysis of HIV-1 and SIV-specific ADCC-
mediating antibody responses. Cytometry A 79:603–612. http://dx.doi
.org/10.1002/cyto.a.21084.
22. Harrison A, Colvin CJ, Kuo C, Swartz A, Lurie M. 2015. Sustained high
HIV incidence in youngwomen in southernAfrica: social, behavioral, and
structural factors and emerging intervention approaches. Curr HIV/AIDS
Rep 12:207–215. http://dx.doi.org/10.1007/s11904-015-0261-0.
23. Barnett SW, Srivastava IK, Kan E, Zhou F, Goodsell A, Cristillo AD,
Ferrai MG, Weiss DE, Letvin NL, Montefiori D, Pal R, Vajdy MM.
2008. Protection of macaques against vaginal SHIV challenge by systemic
or mucosal and systemic vaccinations with HIV-envelope. AIDS 22:339–
348. http://dx.doi.org/10.1097/QAD.0b013e3282f3ca57.
24. Lue J, Hsu M, Yang D, Marx P, Chen Z, Cheng-Mayer C. 2002. Addition
of a single gp120 glycan confers increased binding to dendritic cell-specific
ICAM-3-grabbing nonintegrin and neutralization escape to human im-
munodeficiency virus type 1. J Virol 76:10299–10306. http://dx.doi.org
/10.1128/JVI.76.20.10299-10306.2002.
25. Nuttall J, Kashuba A, Wang R, White N, Allen P, Roberts J, Romano
J. 2012. Pharmacokinetics of tenofovir following intravaginal and in-
trarectal administration of tenofovir gel to rhesus macaques. Antimi-
crob Agents Chemother 56:103–109. http://dx.doi.org/10.1128/AAC
.00597-11.
26. Karim SS, Kashuba AD, Werner L, Karim QA. 2011. Drug concentra-
tions after topical and oral antiretroviral pre-exposure prophylaxis: impli-
cations for HIV prevention in women. Lancet 378:279–281. http://dx.doi
.org/10.1016/S0140-6736(11)60878-7.
27. Lewis DJ, Fraser CA, Mahmoud AN, Wiggins RC, Woodrow M, Cope
A, Cai C, Giemza R, Jeffs SA, Manoussaka M, Cole T, Cranage MP,
Shattock RJ, Lacey CJ. 2011. Phase I randomised clinical trial of an
HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered
vaginally. PLoS One 6:e25165. http://dx.doi.org/10.1371/journal.pone
.0025165.
28. Cranage MP, Fraser CA, Cope A, McKay PF, Seaman MS, Cole T,
Mahmoud AN, Hall J, Giles E, Voss G, Page M, Almond N, Shattock RJ.
2011. Antibody responses after intravaginal immunisation with trimeric
HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic
priming or boosting with an adjuvanted formulation. Vaccine 29:1421–
1430. http://dx.doi.org/10.1016/j.vaccine.2010.12.034.
29. Seaton KE, Ballweber L, Lan A, Donathan M, Hughes S, Vojtech L,
Moody MA, Liao HX, Haynes BF, Galloway GG, Richardson BA, Karim
SA, Dezzutti CS, McElrath MJ, Tomaras GD, Hladik F. 2014. HIV-1
specific IgA detected in vaginal secretions of HIV uninfected women par-
ticipating in a microbicide trial in southern Africa are primarily directed
toward gp120 and gp140 specificities. PLoS One 9:e101863. http://dx.doi
.org/10.1371/journal.pone.0101863.
30. Pattacini L, Murnane PM, Baeten JM, Fluharty TR, Thomas KK,
Bukusi E, Katabira E, Mugo N, Donnell D, Lingappa JR, Celum C,
Marzinke M, McElrath MJ, Lund JM, Partners PrEP Study Team. 2015.
Antiretroviral pre-exposure prophylaxis does not enhance immune re-
sponses to HIV in exposed but uninfected persons. J Infect Dis 211:1943–
1952. http://dx.doi.org/10.1093/infdis/jiu815.
31. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drum-
mond DD, Legasse AW, Axthelm MK, Oswald K, Trubey CM, Piatak
MJR, Lifson JD, Nelson JA, Jarvis MA, Picker LJ. 2009. Effector memory
T cell responses are associated with protection of rhesus monkeys from
mucosal simian immunodeficiency virus challenge. Nat Med 15:293–299.
http://dx.doi.org/10.1038/nm.1935.
32. Barouch DH, Klasse PJ, Dufour J, Veazey RS, Moore JP. 2012. Macaque
studies of vaccine and microbicide combinations for preventing HIV-1
sexual transmission. Proc Natl Acad Sci U S A 109:8694–8698. http://dx
.doi.org/10.1073/pnas.1203183109.
33. Cheng-Mayer C, Huang Y, Gettie A, Tsai L, Ren W, Shakirzyanova M,
Sina ST, Trunova N, Blanchard J, Jenkins LM, Lo Y, Schito ML, Appella
E. 2011. Delay of simian human immunodeficiency virus infection and
control of viral replication in vaccinatedmacaques challenged in the pres-
ence of a topical microbicide. AIDS 25:1833–1841. http://dx.doi.org/10
.1097/QAD.0b013e32834a1d94.
34. Minnis AM, van der Straten A, Salee P, Hendrix CW. 13 May 2015.
Pre-exposure Prophylaxis Adherence Measured by Plasma Drug Level
in MTN-001: Comparison between vaginal gel and oral tablets in two
geographic regions. AIDS Behav http://dx.doi.org/10.1007/s10461
-015-1081-3.
35. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD,
Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao
HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H,
DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML,
Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA,
Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL,
Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S,
Rerks-Ngarm S, Michael NL, Kim JH. 2012. Immune-correlates analysis
of an HIV-1 vaccine efficacy trial. N Engl J Med 366:1275–1286. http://dx
.doi.org/10.1056/NEJMoa1113425.
36. Dawson L, Garner S, Anude C, Ndebele P, Karuna S, Holt R, Broder G,
Handibode J, Hammer SM, MESobieszczy K, NIAID HIV Vaccine
Trials Network. 2015. Testing the waters: ethical considerations for in-
cluding PrEP in a phase IIb HIV vaccine efficacy trial. Clin Trials 12:394–
402. http://dx.doi.org/10.1177/1740774515579165.
Le Grand et al.
5328 jvi.asm.org June 2016 Volume 90 Number 11Journal of Virology
 o
n
 M
ay 17, 2016 by Im
perial College London
http://jvi.asm.org/
D
ow
nloaded from
 
